Navigation Links
Data Presented at Digestive Disease Week Highlights Additional Analysis of DIFICID™ Phase 3 Data
Date:5/9/2011

"The data from this study demonstrate that patients treated with fidaxomicin were significantly less likely to suffer a relapse of the initial infection within the first two weeks after completing therapy. The data also suggest that late recurrence is likely due to a reinfection from the environment, particularly in patients with risk factors such as elevated white blood cells and low albumin levels at the end of therapy and exposure to concomitant antibiotics."

The second poster presented today demonstrates that DIFICID is minimally absorbed with plasma levels in the low ng/mL range while maintaining high fecal concentration that are well in excess of the MIC90 versus C. difficile. The analysis measured the concentration of DIFICID and its metabolite, OP-1118, in the plasma and feces of patients treated with the drug in the Phase 3 clinical studies. Plasma concentrations were in the low nanogram per milliliter (ng/mL) range for both DIFICID and its metabolite at day 1 and at End-of-Therapy.  By contrast with the plasma concentrations, fecal concentrations were more than 10,000 times higher as fecal levels exceeded 1,000 micrograms/gram (ug/g) for DIFICID and 800 ug/g for its metabolite.  The DIFICID fecal levels were more than 1,000 times the minimum inhibitory concentration for C. difficile of 0.25 ug/mL and consistent with a high level of activity toward the target organism at the intended site of action in the colon.  The poster presentation is titled "High Fecal and Low Plasma Levels of Fidaxomicin and Metabolite OP-1118 in Patients with C. difficile infection:  Combined Results of Two Phase 3 Trials."

"Following oral administration, DIFICID has minimal systemic exposure, even in patients with CDI," said Pam Sears, Ph.D., Executive Director of Biology and Pre-Clinical Science at Optimer.  "These data show that DIFICID tends to stay in the site of infection for this disease."

About DIFICID™
'/>"/>

SOURCE Optimer Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine technology :

1. Rhythmia Medical Highlights Studies to be Presented at Heart Rhythm Society 2011 Annual Scientific Session
2. ConvaTec Supported Studies to be Presented at the 24th Annual Symposium on Advanced Wound Care (SAWC) and Wound Healing Society (WHS)
3. New Study Results Presented on Dexlansoprazole and Lansoprazole Effects on Plavix® (clopidogrel bisulfate)
4. Three Studies Presented at the 2011 SHEA Annual Scientific Meeting Show That the ICU Medical MicroCLAVE® Contributes to a Significant Decrease in Bacterial Transfer and Reduction in Bloodstream Infections
5. REMEDIAL II Results on PLC Systems RenalGuard® to be Presented at ACC 2011s Late Breaking Clinical Trial Session
6. Long-Term Data on QNEXA® to be Presented at The American College of Cardiology Annual Meeting
7. Cinryze® (C1 Esterase Inhibitor [Human]) Data Presented at 2011 American Academy of Allergy Asthma & Immunology (AAAAI) Annual Meeting
8. Advancements in GYN Oncology; Instrumentation and Techniques to be Presented by Nicholas C. Lambrou, M.D. of Miami
9. Urocidin™ Phase III Clinical Trial Results to be Presented at EAU and AUA Conferences
10. New England Patriots Offensive Line Wins Second Annual Madden Most Valuable Protectors Award Presented by Prilosec OTC®
11. New Clinical Study Presented at the American Association of Respiratory Care Finds Masimo Rainbow Acoustic Monitoring Accurate for Respiration Rate Assessment
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/18/2013)... NEW YORK , May 18, 2013 /PRNewswire/ ... securities law firm, is investigating potential securities fraud ... (NASDAQ: AVEO). (Logo: http://photos.prnewswire.com/prnh/20120119/MM38856LOGO ... the Company and its executives violated federal securities ... regarding the Company,s Phase III drug trials for ...
(Date:5/17/2013)... 2013 Medical devices are any medical items ... In light of their different mechanisms, actions and regulatory ... complicated than drug trails due to their unique clinical ... of evaluating both safety and efficacy (which is left ... the same as the SFDA) evaluate MDs for both ...
(Date:5/17/2013)...  Sorrento Therapeutics, Inc. (OTCBB: SRNE; or STI) ... Business Technology Transfer Research (STTR) grant (#1R42AI098182-02) from ... (NIAID), a division of the National Institutes of ... antibody therapeutics to combat Staphylococcus aureus ... methicillin-resistant S. aureus (MRSA), was renewed ...
Breaking Medicine Technology:Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses In Excess Of $100,000 Investing In AVEO Pharmaceuticals, Inc. To Contact The Firm 2Statistical Challenges in Medical Device Trail Evaluation 2Sorrento Therapeutics, Inc. announces its approach to developing human antibody therapeutics against MRSA receives continued support from the National Institute of Allergy and Infectious Diseases 2Sorrento Therapeutics, Inc. announces its approach to developing human antibody therapeutics against MRSA receives continued support from the National Institute of Allergy and Infectious Diseases 3Sorrento Therapeutics, Inc. announces its approach to developing human antibody therapeutics against MRSA receives continued support from the National Institute of Allergy and Infectious Diseases 4
... indicates that anti-inflammatory drugs may become a new tool ... leading global cause of death. In investigating a specific ... researchers used the Cardiochip, a gene analysis tool designed ... Center for Applied Genomics at The Children,s Hospital of ...
... March 14, 2012 OncoSec Medical Incorporated ... Medical System (OMS) ElectroOncology therapies to treat solid ... Institute in Santa Monica, CA, and Lakeland Comprehensive ... as enrolling sites, and investigators are screening patients ...
Cached Medicine Technology:Gene Chip, Invented by Children's Hospital of Philadelphia Scientist, Pinpoints New Target to Prevent Heart Disease 2Gene Chip, Invented by Children's Hospital of Philadelphia Scientist, Pinpoints New Target to Prevent Heart Disease 3OncoSec Initiates Two Additional Clinical Sites for Phase II Metastatic Melanoma Trial 2OncoSec Initiates Two Additional Clinical Sites for Phase II Metastatic Melanoma Trial 3OncoSec Initiates Two Additional Clinical Sites for Phase II Metastatic Melanoma Trial 4
(Date:5/19/2013)... May 19, 2013 The report “Feed ... Trends & Forecasts up to 2017” published by MarketsandMarkets, ... with analysis and forecasting of the global volume and ... the driving and restraining factors for the global market ... and challenges. The market is segmented and revenue is ...
(Date:5/19/2013)... 19, 2013 Farming methods have changed ... the ground 10,000 years ago. Most recently, the Green ... by using genetically engineered seeds and by applying chemical ... backlash to these techniques due to the adverse environmental ... a corresponding surge in interest in organic, sustainable farming ...
(Date:5/19/2013)... (PRWEB) May 19, 2013 Yeast infections are ... appear in sensitive areas of the human body. A new ... This new formula provides a unique method of application to ... spray solution is now provided to men and women searching ... naturally absorbed in the body through food and is stored ...
(Date:5/19/2013)... (PRWEB) May 19, 2013 Beginning Wednesday, May ... Valley Blood Center (RRVBC) will feature “Hot Dog Wednesdays" and ... RRVBC will provide hot dogs and all the fixin's ... slushies each day throughout the summer. “Donors are our lifeline. ... a stable and adequate blood supply. This is a ...
(Date:5/19/2013)... Minor fender benders and serious car ... parties to the accident to respond appropriately to the ... Prevention (CDC) data from 2010, accidents, including car accidents, ... In fact, in 2005, automobile accident-related deaths ... than 2.3 million drivers and passengers receive treatment in ...
Breaking Medicine News(10 mins):Health News:Feed Additives Market to Reach $19.5 Billion by 2017 at a CAGR of 3.8% - New Report by MarketandMarkets 2Health News:Feed Additives Market to Reach $19.5 Billion by 2017 at a CAGR of 3.8% - New Report by MarketandMarkets 3Health News:Green Acre Aquaponics Introduces a Revolutionary Approach to Farm Education and Commercial Aquaponics 2Health News:Green Acre Aquaponics Introduces a Revolutionary Approach to Farm Education and Commercial Aquaponics 3Health News:A Safe & Homeopathic Yeast Infection Relief by Yeastrol Now Available at HealthCareSupplementz.com with Massive Discount 2Health News:Hot Dog Wednesdays and Ice Cold Slushies Return to Rock River Valley Blood Center for the Summer 2Health News:Auto Accident Infographic Issued by d’Oliveira & Associates on Steps to Take After a Car Crash 2
... ... superior performance in cell culture and addresses the need for animal-free transferrin in many ... , ... CO (PRWEB) September 16, 2009 -- InVitria today announced the launch of Optiferrin ...
... Hoffa Denounces 35 Percent Excise Tax on Higher-Cost Plans , ... said the proposal to impose a 35 percent tax on insurers for individual ... , , The proposal, introduced by Senate Finance Committee Chairman ... $21,000. , , "We,re pleased that Sen. Baucus stopped ...
... , , MINNEAPOLIS, Sept. ... announced the first ever meeting of thought leading spine surgeons to ... SI Joint pathology, a frequent cause of low back pain. ... included Steven Garfin (former president of NASS, Chief of Orthopedics at ...
... WASHINGTON, Sept. 16 Today U.S. Sen. Max Baucus (D-MT) ... of 2009" that will be marked-up in the Senate Financial ... (Logo: http://www.newscom.com/cgi-bin/prnh/20080930/FRCLOGO ) , , The ... that cover all elective abortions and moves well beyond the ...
... them directly related to success, study shows , WEDNESDAY, Sept. ... suspect they are in the middle of cardiac arrest, push ... more pushes, the better. , That,s the message of a ... related to the amount of time spent doing chest compressions ...
... NEW YORK, Sept. 16 As fall approaches, many women ... skinny jeans has you feeling uneasy, think again. Here,s more ... jeans. , , Listen to this report from ... Registered journalists can access video, audio, text, graphics and photos ...
Cached Medicine News:Health News:InVitria Successfully Completes Beta Testing and Announces Commercial Launch of Optiferrin for Mammalian Cell Culture 2Health News:Teamsters Oppose Baucus Plan to Tax Health Insurance Companies 2Health News:Academic Opinion Leaders in the Field of Spine Surgery & Sacroiliac Joint Experts Attend SI-BONE's National Summit on the Diagnosis of Sacroiliac Pathology 2Health News:Academic Opinion Leaders in the Field of Spine Surgery & Sacroiliac Joint Experts Attend SI-BONE's National Summit on the Diagnosis of Sacroiliac Pathology 3Health News:Academic Opinion Leaders in the Field of Spine Surgery & Sacroiliac Joint Experts Attend SI-BONE's National Summit on the Diagnosis of Sacroiliac Pathology 4Health News:Family Research Council: Senator Baucus Undermines President Obama's Abortion Funding Claim 2Health News:More Chest Compressions During CPR Improves Survival Odds 2
... Xtra™, and Maximum ACT™ introducers ... standard and specialty hemostasis introducers ... recognized as the premier hemostasis ... cardiology and electrophysiology procedures including ...
Lumenis 950 Slit Lamp Zeiss-style diagnostic slit lamp biomicroscope with parallel optics and offering a choice of automatic or fixed eye safety filters for multiple wavelengths....
... Adding the S-Link LaserLink to ... Selecta Duo, a versatile Nd:YAG ... laser that extends treatment capabilities ... anterior segment and posterior pole ...
... The Apeel CS Catheter Delivery System ... used for the placement of permanent ... Apeel CS Catheter Delivery System is ... torqueability, flexibility, and softness, plus high ...
Medicine Products: